Skip to main content

Table 5 Range of bedaquiline prices and CE analysis based on these ranges

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Bedaquiline price threshold analysisa
  Estonia Russia South Africa Peru China Philippines India
WHO CE thresholds (1x GDP-3x GDP), US$ (Cost per DALY averted) 16,844 – 50,532 14,037 – 42,111 7,352 – 22,056 6,796 – 20,388 6,091 - 18,273 2,587 – 7,761 1,503 – 4,509
Cost-effective price range, US$b 91,984 – 203,492 73,909 – 156,427 29,151 – 72,701 36,421 – 92,953 23,904 – 62,593 8,567 – 22,992 6,996 – 20,323
Bedaquiline plus BR vs. BR alone price range for cost-effectiveness analysis
 Half lowest range price, US$ 45,992 36,955 14,576 18,211 11,952 4,284 3,498
 Lowest range price, US$ 91,984 73,909 29,151 36,421 23,904 8,567 6,996
 Mid-range price, US$ 147,738 115,168 50,926 64,687 43,428 15,285 13,660
 Highest-range price, US$ 203,492 156,427 72,701 92,953 62,593 22,002 20,323
 Double highest range price, US$ 406,984 312,854 145,402 185,906 125,186 44,004 40,646
  1. BR background regimen, CE cost-effectiveness, DALY disability-adjusted life years, GDP gross domestic product, US United States, WHO World Health Organization
  2. aPrice ranges were chosen in order to satisfy the WHO CE threshold (up to 3x GDP of each country)
  3. bPer 6-month regimen